Abstract
Two series A and B of 12 and 7 new carbamate derivates were tested in vitro as acetylcholinesterase inhibitors. The tests were performed in the batch stirred reactor at 25°C, pH 8, ionic strength 0.11 M and catalytic activity of the enzyme preparation 0.14 U mL-1 of the reaction mixture. The temporal dependences of actual concentrations of acetylcholine, choline and acetic acid were determined by two independent analytical methods, HPLC and pH-stat. For all used inhibitors, the model of competitive irreversible inhibition was valid. The inhibition rate constant k3 and qualified estimation of the absolute acetylcholinesterase concentration in the reaction mixture were calculated. The partition coefficients Kow between n-octanol and water of all used inhibitors were determined. The k3 and Kow values were correlated with the Hammett and Hansch substituent constants and with the calculated docking and binding energies of the reaction between the tested inhibitors and acetylcholinesterase.
Keywords: Acetylcholine, hydrolysis, enzymatic, in vitro, acetylcholinesterase, carbamates, inhibition, kinetics, HPLC, docking energies
Current Enzyme Inhibition
Title:Kinetics of In Vitro Inhibition of Acetylcholinesterase by Nineteen New Carbamates
Volume: 7 Issue: 4
Author(s): Marketa Kovarova, Mahmud T.H. Khan, Karel Komers, Patrik ParÃk, Alexander Cegan, Martina Zatloukalova
Affiliation:
Keywords: Acetylcholine, hydrolysis, enzymatic, in vitro, acetylcholinesterase, carbamates, inhibition, kinetics, HPLC, docking energies
Abstract:
Two series A and B of 12 and 7 new carbamate derivates were tested in vitro as acetylcholinesterase inhibitors. The tests were performed in the batch stirred reactor at 25°C, pH 8, ionic strength 0.11 M and catalytic activity of the enzyme preparation 0.14 U mL-1 of the reaction mixture. The temporal dependences of actual concentrations of acetylcholine, choline and acetic acid were determined by two independent analytical methods, HPLC and pH-stat. For all used inhibitors, the model of competitive irreversible inhibition was valid. The inhibition rate constant k3 and qualified estimation of the absolute acetylcholinesterase concentration in the reaction mixture were calculated. The partition coefficients Kow between n-octanol and water of all used inhibitors were determined. The k3 and Kow values were correlated with the Hammett and Hansch substituent constants and with the calculated docking and binding energies of the reaction between the tested inhibitors and acetylcholinesterase.
Export Options
About this article
Cite this article as:
Marketa Kovarova, Mahmud T.H. Khan, Karel Komers, Patrik ParÃk, Alexander Cegan, Martina Zatloukalova , Kinetics of In Vitro Inhibition of Acetylcholinesterase by Nineteen New Carbamates, Current Enzyme Inhibition 2011; 7 (4) . https://dx.doi.org/10.2174/157340811799860560
DOI https://dx.doi.org/10.2174/157340811799860560 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Conference Report: 12<sup>th</sup> International Congress on Neuroprotective Agents (ICNA), Charlottesville, VA, USA September 28, 2014-Ocobert 01, 2014
CNS & Neurological Disorders - Drug Targets Mechanisms of Synaptic Homeostasis in Alzheimers Disease
Current Alzheimer Research The Effects of Psychological Stress on Depression
Current Neuropharmacology Oxidative Stress Mediated Mitochondrial and Vascular Lesions as Markers in the Pathogenesis of Alzheimer Disease
Current Medicinal Chemistry Drug-Delivery Systems of Green Tea Catechins for Improved Stability and Bioavailability
Current Medicinal Chemistry Neurodegenerative Diseases of the Retina and Potential for Protection and Recovery
Current Neuropharmacology A Point of View: The Need to Identify an Antigen in Psyconeuroimmunological Disorders
Current Pharmaceutical Design Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Statin Treatment and Carotid Plaque Composition: A Review of Clinical Studies
Current Vascular Pharmacology Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India
Current Vascular Pharmacology Vitamins Mediate Immunological Homeostasis and Diseases at the Surface of the Body
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Thematic Issue: Endocrine Disorders and Cognitive Function in the Elderly)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk
Current Pharmaceutical Design A Summary of Electrospun Nanofibers as Drug Delivery System: Drugs Loaded and Biopolymers Used as Matrices
Current Drug Delivery Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography
Current Pharmaceutical Design Spatio-Temporal Fluctuations of Neural Dynamics in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Editorial: “Phytochemicals for Human Diseases: An Update”
Current Drug Targets Genomic and Pharmacogenomic Biomarkers of Parkinson’s Disease
Current Drug Metabolism Severe Acute Respiratory Syndrome Coronavirus 2 is Penetrating to Dementia Research
Current Neurovascular Research Genetic Factors in Parkinsons Disease and Potential Therapeutic Targets
Current Neuropharmacology